Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Sixteen trials, including 11,402 participants (mean age 73.2 [±5.5] years; 62.3 % female) were examined.
-
We identified fifty studies (N=1,548,754).
-
Of 300 randomized participants, 277 participants (mean age, 72.9 years; 69.3% female) were included in the modified intention-to-treat analysis (142 in the MLI group and 135 in the control group).
-
Fourteen cohorts including 726,900 participants were analyzed.
-
Vision impairment (VI) and eye diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and cataract have been reported to be associated with cognitive impairment and dementia, however, to date, very little attempt has been made to collate and synthesizes such literature.
-
General baseline characteristics of the study population were mean (standard deviation) age, 58.1 (8.8) years; 47% women.
-
86/100
The meta-analysis showed that hearing impairment is associated with a higher risk of mild cognitive impairment and dementia among older adults.
-
Between March 1, 2016, and March 12, 2020, 383 patients were enrolled and randomly assigned to the intervention or control group.
-
As visual impairment, cataract, and diabetic retinopathy are associated with an increased likelihood of developing dementia, early diagnosis may help identify those at risk of dementia.
-
Visually impaired individuals were more likely to develop incident dementia, with a progressively greater risk among those with worse visual acuity.
-
Data extraction and synthesis This analysis involved random-effects meta-analyses on group-level study results of clinical data and systematic review of the neuroimaging literature.
-
As the first NMA comparing different interventions for AD and MCI, our study suggests that PE and CCT might have a significant improvement in cognition and neuropsychiatric symptoms respectively.
-
83/100
Convergent evidence across the literature supports the use of resting-state connectivity as a biomarker of AD.
-
1,307 patients with SCD and with CDR = 0 at baseline were included.
-
A total of 57 articles were included in the review, including 3182 participants.
-
As the literature related to cognitive reserve (CR) in individuals with frontotemporal dementia (FTD) is only emerging, a clear consensus on the relationship among CR proxies, brain status, and clinical performance has not been reached.
-
Electrophysiological and behavioral tests demonstrated strong correlation and accurate hearing impairment detection compared to PTA.
-
Exercise interventions were performed 3.4 ± 1.4 days per week at moderate intensity (3.7 ± 0.6 metabolic equivalents) for 45.2 ± 17.0 minutes per session for 18.6 ± 10.0 weeks and consisted primarily of aerobic exercise (65%).
-
81/100
In this study, low plasma Aβ42/40 was associated with more pronounced decline in cognitive function (measured by multiple outcomes) over time.
-
ACHIEVE-P sets the stage for the full-scale ACHIEVE trial (N = 850, recruitment beginning November 2017), the first randomized trial to determine efficacy of a best practices hearing (vs. successful aging) intervention on reducing cognitive decline in older adults with HL.
-
Clusters with diffuse or frontal-predominant cortical thinning, but with more favourable vascular profiles, characterized by lower blood pressure and reduced obesity, showed significantly less cortical thinning (mean thickness, AD-signature, and resilience-signature regions; all p < 0.05) following the intervention.
-
In total, 30 studies were included comprising 14,997 subjects.
-
The intervention was feasible and acceptable with the intended number of participants completing the study.
-
80/100
All autonomic networks were positively associated with Aβ42/40 ratio and remained so after adjustment for age, sex, and APOE4 carrier status.
-
Screening commenced in July 2022. Currently, 1,965 participants have been randomized into lifestyle intervention (n = 772) and control groups (n = 1,193).